Alzheimer’s & Dementia - (2014) 1-8
Research Article
Identification of preclinical Alzheimer’s disease by a profile of
pathogenic proteins in neurally derived blood exosomes:
A case-control study
Massimo S. Fiandacaa,1, Dimitrios Kapogiannisb,1, Mark Mapstonec,1, Adam Boxerd,
Erez Eitanb, Janice B. Schwartze, Erin L. Abnerf, Ronald C. Peterseng,
Howard J. Federoffa, Bruce L. Millerd, Edward J. Goetzle,*
a
Departments of Neurology and Neuroscience, Georgetown University Medical Center, Washington, DC, USA
Clinical Research Branch, Intramural Research Program, National Institute on Aging, Baltimore, MD, USA
c
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
d
Department of Neurology, Memory and Aging Center, UCSF Medical Center, San Francisco, CA, USA
e
Department of Medicine, UCSF Medical Center and the Jewish Home of San Francisco, San Francisco, CA, USA
f
Department of Neurology, Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
g
Department of Neurology, Mayo Clinic, Rochester, MN, USA
b
Abstract
Background: Proteins pathogenic in Alzheimer’s disease (AD) were extracted from neurally
derived blood exosomes and quantified to develop biomarkers for the staging of sporadic AD.
Methods: Blood exosomes obtained at one time-point from patients with AD (n 5 57) or frontotemporal dementia (FTD) (n 5 16), and at two time-points from others (n 5 24) when cognitively normal
and 1 to 10 years later when diagnosed with AD were enriched for neural sources by immunoabsorption. AD-pathogenic exosomal proteins were extracted and quantified by enzyme-linked immunosorbent assays.
Results: Mean exosomal levels of total tau, P-T181-tau, P-S396-tau, and amyloid b 1–42 (Ab1–
42) for AD and levels of P-T181-tau and Ab1–42 for FTD were significantly higher than for
case-controls. Step-wise discriminant modeling incorporated P-T181-tau, P-S396-tau, and Ab1–
42 in AD, but only P-T181-tau in FTD. Classification of 96.4% of AD patients and 87.5% of
FTD patients was correct. In 24 AD patients, exosomal levels of P-S396-tau, P-T181-tau, and
Ab1–42 were significantly higher than for controls both 1 to 10 years before and when diagnosed
with AD.
Conclusions: Levels of P-S396-tau, P-T181-tau, and Ab1–42 in extracts of neurally derived blood
exosomes predict the development of AD up to 10 years before clinical onset.
Ó 2014 The Alzheimer’s Association. All rights reserved.
Keywords:
Preclinical AD; Neural exosomes; P-Tau; Ab1–42; Biomarkers
1. Introduction
Roles in the pathogenesis of Alzheimer’s disease (AD)
have been attributed to altered proteins accumulating in-
1
These three authors contributed equally to the reported research.
*Corresponding author. Tel.: 11-703-254-7529; Fax: 11-415-406-1577.
E-mail address: edward.goetzl@ucsf.edu
side and on the surface of neurons [1,2]. Increases in
brain tissue oligomeric amyloid b (Ab) peptides and
phosphorylated tau (P-tau) detected by central nervous
system (CNS) imaging and in cerebrospinal fluid (CSF)
levels of soluble Ab1–42 and P-tau have been
documented years before the signs of AD [3–6]. Times
for progression from preclinical stages to clinically
apparent AD with threshold detectable amyloid
deposition and abnormal elevation of CSF P-tau proteins
1552-5260/$ - see front matter Ó 2014 The Alzheimer’s Association. All rights reserved.
http://dx.doi.org/10.1016/j.jalz.2014.06.008
2
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
are estimated to be up to 17 years [3,5]. The potential
prognostic sensitivity of protein biomarkers is supported
by the timing of induction of AD-like disease in rodent
models after the transgenic overexpression of putatively
neuropathogenic proteins [7–9].
In recent studies, low CSF levels of Ab1–42 and high
CSF levels of P-tau, and positive CNS images of amyloid deposits accurately predicted the development of mild cognitive impairment (MCI) and probable AD [10,11].
However, there was substantial overlap in these
biomarkers between patients who subsequently developed
AD and those who later manifested other forms of
dementia or no signs of dementia, even when
concentrations of these CSF proteins were considered
together or as ratios. The overlap was even greater when
plasma levels of these proteins were used for diagnosis or
prediction [12–15]. This high level of prognostic
uncertainty combined with the morbidity and the expense
of repeated CSF sampling and of neuroimaging procedures
emphasizes the importance of developing accurate bloodbased tests that predict high risk for AD and distinguish
AD from other forms of dementia.
Exosomes are one class of endosome-derived membrane
vesicles shed by neural cells, that contain proteins and other
constituents of their cellular origin [16]. Exosomes accept
amyloid precursor protein from early endosomes, after its
cleavage by b-secretase, and the Ab peptide fragments subsequently generated by g-secretase are secreted in exosomes [17]. Although this exosome pathway accounts for
only a small portion of the total Ab peptides in neural plaques, it constitutes a prionoid-like mechanism for CNS
spread of proteinopathies [18]. The detection of exosome
signature proteins in neural amyloid plaques supports the
possibility of their role in the generation of ADassociated lesions [17]. Here we use a combination of
chemical and immunochemical methods to harvest and
enrich neurally derived exosomes from small volumes of
plasma or serum in quantities that provide readily detectable amounts of proteins implicated in the pathogenesis
of AD.
2. Materials and methods
2.1. Study design, subject characterization, and blood
collection
Fifty-seven patients with amnestic MCI (aMCI) or dementia attributable to AD, who had donated blood at one
time-point, were identified retrospectively at the Clinical
Research Unit of the National Institute on Aging (CRUNIA) in Harbor Hospital, Baltimore, MD, at the Jewish
Home of San Francisco (JHSF), San Francisco, CA, and
in the neurology clinical services of the University of Rochester (UR), Rochester, NY, the University of California
Irvine (UCI), Irvine, CA, and Georgetown University
Medical Center, Washington, DC (GUMC) (Table 1).
Twenty-four additional patients with AD had provided
blood at two time-points in studies at the Mayo Clinic
and the University of Kentucky, first when cognitively
intact and later when diagnosed with AD. For both
groups, the diagnosis of AD had been established according to the revised National Institute of Neurological and
Communicative Disorders and Stroke and Alzheimer’s
Disease and Related Disorders Association (NINDSADRDA) criteria [19]. The patients classified as having
aMCI had a Clinical Dementia Rating (CDR) global score
of 0.5 [20]. Those with AD and mild to moderate dementia had a CDR global score of 1.0. Twenty-eight of the 57
single-time sample AD patients were taking an acetylcholinesterase inhibitor and/or memantine, and 12 were
on antidepressant medications; blood was drawn at least
8 hours after their last medication.
Sixteen patients with behavioral variant frontotemporal
dementia (bv-FTD) had been evaluated and selected for
study at the Memory and Aging Center of the Department
of Neurology of the University of California, San Francisco (Table 1). Their diagnosis and assignment to mild
dementia or moderate dementia groups (Table 1) was
based on standard clinical, mental status, and psychiatric
criteria, including discriminant analyses of neuropsychiatric elements, phonological performance, and object understanding that distinguish FTD from AD [21,22]. Seven
Table 1
Characteristics of patients and control subjects
Total
MCI
Dementia
MMSE scores,
mean 6 SEM
Diagnosis
Number
Male/female
Ages, mean 6 SD (range)
Number
AD
AC
57
57
30/27
30/27
79.5 6 6.05 (64–90)
79.6 6 6.03 (64–90)
FTD
FTC
16
16
12/4
12/4
63.1 6 8.79 (48–79)
63.7 6 7.43 (48–79)
29
27.6 6 0.30
0
Mild dementia
9
26.7 6 0.73
0
Number
MMSE scores,
mean 6 SEM
28
22.9 6 1.02**
0
Moderate dementia
7
15.0 6 3.65*
0
Abbreviations: MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; AD, Alzheimer’s disease; AC, AD case-controls; FTD, frontotemporal dementia; FTC, FTD case-controls.
NOTE. The significance of differences in values between the MCI/mild dementia and dementia/moderate dementia groups were calculated by an unpaired t
test; *P , .01 and **P , .001.
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
of the FTD patients were receiving an antidepressant, two
were taking an acetyl-cholinesterase inhibitor and one
was on memantine. Ninety-two cognitively normal subjects were recruited at the JHSF, CRU-NIA, and GUMC
to be age- and gender-matching controls for the several
groups of AD and FTD patients (five served as controls
for two clinical groups). Each subject studied and some
patient-designates signed a consent form approved with
the study protocol at each institution. All plasma and
serum were stored at 280 C.
2.2. Isolation of exosomes from plasma or serum for
ELISA quantification of exosome proteins
One-half milliliter of plasma was incubated with
0.15 ml of thromboplastin-D (Fisher Scientific, Inc., Hanover Park, IL) at room temperature for 60 minutes, followed by the addition of 0.35 ml of calcium- and
magnesium-free Dulbecco’s balanced salt solution
(DBS22) with protease inhibitor cocktail (Roche Applied
Sciences, Inc., Indianapolis, IN) and phosphatase inhibitor
cocktail (Pierce Halt, Thermo Scientific, Inc., Rockford,
IL). For serum, 0.5 ml was mixed with 0.5 ml of
DBS22 containing the inhibitor cocktails. After centrifugation at 1500 ! g for 20 minutes, supernates were
mixed with 252 ml of ExoQuick exosome precipitation solution (EXOQ; System Biosciences, Inc., Mountainview,
CA), and incubated for 1 hour at 4 C. Resultant exosome
suspensions were centrifuged at 1500 ! g for 30 minutes
at 4 C and each pellet was resuspended in 250 ml of
DBS22 with inhibitor cocktails before the immunochemical enrichment of exosomes from a neural source, as
described for immune cell exosomes [23].
Each sample received 100 ml of 3% bovine serum albumin (BSA; 1:3.33 dilution of Blocker BSA 10% solution
in DBS22 [Thermo Scientific, Inc.]) and was incubated
for 1 hour at 4 C each with 2 mg of mouse anti-human
neural cell adhesion molecule (NCAM) antibody (ERIC
1, sc-106, Santa Cruz Biotechnology, Santa Cruz, CA)
that had been biotinylated with the EZ-Link sulfo-NHSbiotin system (Thermo Scientific, Inc.) or for some preparations with 1 mg of mouse anti-human CD171 (L1 cell
adhesion molecule [L1CAM]) biotinylated antibody
(clone 5G3, eBioscience, San Diego, CA) and then
25 ml of streptavidin-agarose resin (Thermo Scientific,
Inc.) plus 50 ml of 3% BSA. After centrifugation at
200 ! g for 10 minutes at 4 C and removal of the supernate, each pellet was suspended in 50 ml of 0.05 M
glycine-HCl (pH 3.0) by vortexing for 10 seconds. Each
suspension then received 0.45 ml of DBS22 with 2 g/
100 ml of BSA, 0.10% Tween 20 and the inhibitor cocktails followed by incubation for 10 minutes at 37 C with
vortex-mixing and was stored at 280 C before enzymelinked immnuosorbent assays (ELISAs). Relative yields
of exosomes from plasma and serum at this stage were
compared using both sources from six patients with AD.
3
The respective mean levels of P-T181-tau and CD81 extracted from serum-derived exosomes were 58% and
56% of that from plasma-derived exosomes. Although
the yield from serum was lower, it was correctible by
normalization for the exosome marker CD81 as shown
[23]. To recover exosomes for counting, immunoprecipitated pellets were resuspended in 0.25 ml of 0.05 M
glycine-HCl (pH 5 3.0) at 4 C, centrifuged at 200 ! g
for 15 minutes and supernate pH adjusted to 7.0 with
1 M Tris-HCl (pH 8.6). Exosome suspensions were
diluted 1:200 to permit counting in the range of 3–
15 ! 108/ml, with an NS500 nanoparticle tracking system (NanoSight, Amesbury, UK), as described [23].
Exosome proteins were quantified by ELISA kits for
human Ab1–42, human total tau, and human P-S396-tau
(Life Technologies/Invitrogen, Camarillo, CA), human
P-T181-tau (Innogenetics Division of Fujirebio US, Inc.,
Alpharetta, GA) and human CD81 (H€olzel DiagnostikaCusabio, Cologne, Germany) with the verification of the
CD81 antigen standard curve using human purified recombinant CD81 antigen (Origene Technologies, Inc.,
Rockville, MD), according to suppliers’ directions. The
mean value for all determinations of CD81 in each assay
group was set at 1.00 and the relative values for each sample used to normalize their recovery. The minor constituent of secreted neural exosomes P-S396-tau and the
usually examined major neural exosome component PT181-tau were both quantified to provide more complete
information about the possible relationship between
neurally secreted and plasma neurally derived exosome
constituents in AD and FTD [24].
2.3. Statistical analyses
The statistical significance of differences between
group means for patients with AD or FTD and their
respective normal controls was determined with an unpaired t test including a Bonferroni correction in the interpretation (GraphPad Prism 6, La Jolla, CA). The
significance of differences between serial values for AD
patients taken before and after the onset of aMCI or dementia was calculated with a paired t test (GraphPad).
Separate discriminant classifier analyses were conducted
to define the best simple linear models for comparing
AD with AC and FTD with FTC. Two discriminant
analyses considered all variables and were performed
step-wise. Final models retained only variables with a
minimum partial F of 3.84 to enter and 2.71 to remove.
Prior probabilities were considered equal for all groups.
Fisher function coefficients and within group covariances
were computed. Receiver operating characteristics (ROC)
analyses were conducted under the nonparametric distribution assumption for standard error of area to determine
the performance of the models for discriminating AD
from AC and FTD from FTC. Discriminant and ROC analyses were conducted with SPSS v21.0 (IBM).
4
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
3. Results
3.1. Patient characteristics
The 57 patients with AD consisted nearly equally of those
with aMCI or dementia, with the latter group having significantly lower MMSE scores (P , .001) (Table 1). The 16 patients with FTD had nearly equal numbers with mild or
moderate dementia, with greater severity for the latter group
documented by the significantly lower MMSE scores
(P , .01). As cognitively normal control subjects were
matched individually with patients, group male/female ratios, and mean (6SD) ages were expectedly nearly equal.
3.2. Exosomal protein levels
Cross-sectional comparisons of results of one-time studies
of 57 AD patients and 57 matched case-controls (AC) revealed
that AD exosomal concentrations of total tau (191 6 12.3 pg/
ml, mean 6 SEM, P 5.0005), P-T181-tau (106 6 6.10 pg/ml,
P , .0001), P-S396-tau (25.4 6 2.25 pg/ml, P , .0001), and
Ab1–42 (18.5 6 2.97 pg/ml, P , .0001) were significantly
higher than for AC (130 6 11.9 pg/ml, 16.9 6 1.89 pg/ml,
3.88 6 0.26 pg/ml, and 0.83 6 0.13 pg/ml, respectively)
(Fig. 1). P-S396-tau levels showed the least overlap with
only five AD values in the AC range, of which two had PT181-tau levels, two others had Ab1–42 levels, and one had
both P-T181-tau and Ab1–42 levels above the AC range.
Thus the AD profile of these three exosomal proteins together
was completely distinct from that of AC. Step-wise discriminant analyses resulted in a model progressively incorporating
P-T181-tau, P-S396-tau, and Ab1–42, but not total tau, which
produced a Wilk’s lambda of 0.229 and an exact F of 119
(P , .001). The final model correctly classified 96.4% of
MCI/AD patients contrasted with AC subjects (93% of
MCI/AD and 100% of AC). The area under the curve
(AUC) for the final model from the ROC analysis was 0.999
and individual AUC values for the individual proteins were
0.991, 0.988, 0.987, and 0.731, respectively, for P-T181-tau,
P-S396-tau, Ab1–42, and total tau (Fig. 1S).
Cross-sectional comparisons of the results of one-time
studies of 16 FTD patients and 16 matched case-controls
(FTC), showed that FTD exosomal concentrations of PT181-tau (82.6 6 9.20 pg/ml, mean 6 SEM) and Ab1–42
(7.54 6 1.01 pg/ml) were significantly higher than for the
FTC group (9.32 6 2.86 pg/ml and 0.76 6 0.35 pg/ml,
respectively; both P , .0001), whereas those of total tau
and P-S396-tau did not differ significantly between the
FTD (135 6 15.8 pg/ml and 2.13 6 0.33 pg/ml, respectively) and FTC (148 6 30.1 pg/ml and 3.13 6 0.46 pg/
ml) groups (Fig. 1). Fourteen of the 16 levels of P-T181tau for FTD patients were higher than the upper end of the
range for FTC subjects and the Ab1–42 levels for the two
FTD patients with P-T181-tau levels in the FTC range
both were above the FTC Ab1–42 range. In a step-wise
discriminant analysis, only P-T181-tau entered the model,
and attained a Wilk’s Lambda value of 0.324 and an exact
F of 62.5 (P , .001). In the final model, exosomal PT181-tau correctly classified 87.5% of FTD patients contrasted with FTC subjects (75% of FTD and 100% of
FTC). For the final model from the ROC analysis, AUC
Fig. 1. Levels of proteins in blood exosomes of patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and cognitively normal matched casecontrols (AC, FTC). The horizontal line in each cluster here and in Fig. 2 depicts the mean for that set.
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
for P-T181-tau was 0.992 and for Ab1–42 was 0.969. Most
remarkably and in contrast to the AD group, none of the concentrations of P-S396-tau for the FTD group was higher than
the upper end of the range for the FTC subjects.
Resuspended initial precipitates from control subjects
(n 5 3) and AD patients with dementia (n 5 3), respectively,
contained 3.49 6 0.90 ! 109 exosomes/ml of plasma
(mean 6 SEM) and 2.78 6 0.26 ! 109 exosomes/ml of
plasma as determined by the Nanosight system. Suspensions
of immunoabsorbed exosomes from the same initial suspensions contained 0.417 6 0.023 ! 109 exosomes/ml of
plasma and 0.472 6 0.090 ! 109 exosomes/ml of plasma.
The range of yields of immunoabsorbed neurally derived
exosomes for both AD and AC groups was 12% to 17% of
the initial precipitates. Diameters of total plasma exosomes
and immunoabsorbed putatively neural plasma exosomes
ranged from 78 nm to 126 nm, which encompasses the expected exosomal size. No difference between exosomes of
AD patients and control subjects was statistically significant,
so that differences in the levels of pathogenic proteins are not
due to divergent yields of exosomes and have been corrected
by normalization with the exosomal marker CD81.
To support the capacity of neural adhesive protein immunoabsorption to enrich plasma exosomes from a neural
source, immunoabsorption was carried out in parallel both
with anti-NCAM-1 antibody and anti-L1CAM antibody
for six plasmas of AD patients and six plasmas of matched
controls (Table S1). Unlike the anti-NCAM-1 antibody, the
anti-L1CAM antibody does not bind to NK and NKT cells
of the immune system and is differently distributed in the
nervous system. Extracted exosomal levels of CD81, PT181-tau, P-S396-tau, total tau, and Ab1–42 were statistically indistinguishable whether enriched with anti-NCAM1 antibody or anti-L1CAM antibody.
3.3. Relationship of exosomal protein levels to severity
and stage of AD
Comparing the 29 AD patients with aMCI to the 28 AD
patients with dementia showed no differences in the exosomal levels of P-S396-tau, P-T181-tau, total tau, or Ab1–42
(Table 2). This suggested that increased exosomal levels of
these pathogenic proteins might be detectable early in the
preclinical course. Blood exosomal proteins therefore were
measured for an additional group of 24 AD patients at two
time-points, the first at 1 to 10 years before their diagnosis
Table 2
Levels of serum exosome proteins in relation to severity of dementia in AD
Patient group
P-S396-tau
P-T181-tau
Total tau
Ab1–42
AD, MCI
AD, dementia
23.8 6 3.27
27.0 6 3.12
114 6 10.6
102 6 7.08
201 6 20.9
181 6 12.8
23.0 6 4.57
12.8 6 1.60
Abbreviations: Ab1–42, amyloid b1-42; AD, Alzheimer’s disease; MCI,
mild cognitive impairment.
NOTE. All values are mean 6 SEM, pg/ml; none of the differences between values for the MCI and dementia groups were significant.
5
and the second at the time of initial diagnosis of AD. This
group consisted of 12 men and 12 women with a mean age
(6SD) of 71.8 6 7.30 years at the time of the first blood
sample. The later diagnosis was aMCI for 13 and dementia
for 11. Intervals between the two blood samples (number
of patients) were: 1 year (one), 2 years (one), 3 years
(four), 4 years (two), 5 years (two), 6 years (two), 7 years
(three), 8 years (three), 9 years (three), and 10 years (three).
As for the single time-point values (Fig. 1), the mean
levels (6SEM) of P-S396-tau (25.2 6 1.85 pg/ml), PT181-tau (91.1 6 4.42 pg/ml), and Ab1–42 (14.5 6 1.41
pg/ml) at the time of diagnosis of AD were significantly
higher than those of their case-controls (AC) (4.72 6 0.64
pg/ml, 35.6 6 3.49 pg/ml and 1.51 6 0.52 pg/ml, respectively; all P , .0001) (Fig. 2). The mean level of total tau
for the AD patients (165 6 15.8 pg/ml) was no different
from that of their AC group (148 6 16.5 pg/ml). Furthermore, the mean preclinical (AP) level of total tau
(154 6 13.6 pg/ml) also was no different from that of AC.
For P-S396-tau and P-T181-tau, the AP (19.2 6 2.00 pg/
ml and 85.7 6 3.75 pg/ml, respectively) and AD values
were significantly higher than those of the corresponding
AC sets (both P , .0001). The mean P-S396-tau and PT181-tau values of the AD group were no different from
those of the corresponding AP group. Elevated exosomal
levels of P-S396-tau and P-T181-tau thus were clearly
detectable in a high-risk but cognitively normal AP group
and had attained a plateau as early as 10 years before the
clinical diagnosis of AD. For Ab1–42, the mean levels for
the AD and AP (6.64 6 0.58 pg/ml) sets both were significantly higher than that of the AC set, but the mean AD level
also was significantly higher than that of AP. Therefore
Ab1–42 may represent a biomarker for progression and
early detection. A comparison of all AP and AD exosomal
protein levels of patients converting to aMCI with those converting to AD did not show any significant differences.
Furthermore, a comparison of all AP and AD exosomal protein levels of patients converting to aMCI or AD after 1 to
5 years with those converting after 6 to 10 years also did
not show any significant differences.
4. Discussion
Levels of total tau, P-T181-tau, P-S396-tau, and Ab1–42
previously quantified in plasma, serum or CSF have represented those in the fluid-phases. In contrast, the levels we
now report are for proteins extracted predominantly from
cellular structures consisting of neurally derived blood exosomes. When contrasted with fluid-phase levels, exosomal
levels are nearly two orders of magnitude higher for total
tau and P-T181-tau, and similar in magnitude for Ab1–42
[15,25–27], and all were significantly greater than those in
case-control exosomes (Fig. 1). When blood exosomal levels
of P-S396-tau, P-T181-tau, and Ab1–42 were considered
together, the sensitivity of distinguishing AD from AC was
96% (Figs. 1 and 2, FigS1). In contrast to levels in AD, no
6
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
Fig. 2. Sequential levels of proteins in blood exosomes of patients with Alzheimer’s disease (AD) measured first at a time of normal cognition (preclinical, AP)
and later at the time of development of amnestic mild cognitive impairment (aMCI) or dementia (AD).
concentration of P-S396-tau for the FTD group was higher
than the upper end of the range for the FTC controls. Thus
blood exosomal P-S396-tau alone separates FTD from AD
with a high specificity. Levels of P-S396-tau, P-T181-tau,
and Ab1–42 together also distinguished patients in the AP
preclinical set from AC subjects with a sensitivity of 96%
(Fig. 2). Most importantly, significantly elevated exosomal
levels of these proteins were detected in high-risk, but cognitively normal AP subjects up to 10 years before clinical diagnosis. Furthermore, blood exosomal levels of Ab1–42
continued to increase progressively from preclinical AP
levels to significantly higher levels at the time of diagnosis
of AD, implying value for exosomal Ab1–42 as a progression biomarker (Fig. 2).
A recent fascinating report of higher or lower than
normal plasma levels of multiple lipids and other cellular
constituents during an average 2.1 year preclinical phase
of AD provided a method with 90% accuracy in predicting
progression to MCI or mild AD [28]. The broad spectrum
of structures, organ distribution, functions, biosynthetic
pathways, and biodegradative mechanisms of these molecules suggest that the disturbed pattern observed reflects
major systemic perturbations in the early stages of AD.
The two sets of results differ in three major respects. First,
here we are assessing neural cell exosomal proteins implicated in the pathogenesis of AD, whereas they quantified
plasma fluid-phase levels of amino acids and fats that are
not characteristically altered in neural lesions of AD. Second, our present approach identified preclinical AD up to
10 years before clinical onset, as contrasted with the detection of plasma abnormalities to date only up to three years
before diagnosis of dementia clinically. Third, the accuracy
of classification of preclinical AD with our protein assays
exceeded 96% as contrasted with 90% for the analyses of
plasma lipids and amino acids. In further collaborative
studies, we quantified neural exosomal P-tau and Ab1-42
proteins in pairs of plasma samples from the 28 AD converters studied earlier by Dr. Federoff’s group [28]. Our results showed significant elevations compared with
cognitively normal matched controls in 100% of the preclinical samples, as contrasted with 89% preclinical identification by the profile of plasma tests of the Georgetown
University Medical Center.
At this point in the evolving understanding of the clinical significance of our findings, it appears that detection
in individuals of elevations of blood exosomal P-T181-tau
and Ab1–42 support the identification of present or future
susceptibility to proteinopathic neurodegenerative
disease, including AD and at least one form of FTD. Concurrent or subsequent recognition of elevated exosomal PS396-tau suggests the presence or future likelihood of
development of AD. At least two more points of information would strengthen the clinical usefulness of this blood
exosomal profile of neuropathogenic proteins. The first
would be quantification of levels of other relevant
neurally derived exosomal proteins, such as TAR DNAbinding protein 43 (TDP-43), fused in sarcoma RNAbinding protein (FUS), and additional isoforms of P-tau,
in relation to the type and severity of neurodegenerative
disease. The second would be results of prospective longitudinal studies designed to delineate the neurological
course of cognitively normal subjects with an abnormal
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
blood exosomal profile of neuropathogenic proteins as
contrasted with the course of those having a normal profile of these proteins. With this knowledge, it may be
possible to identify high-risk subjects early in their preclinical stage, define their point in the preclinical trajectory, and guide early applications of novel treatments.
Acknowledgments
The authors are grateful to Lynn Kane (JHSF), Anna Karydas
(UCSF MAC), Dana Swenson-Dravis and Matthew Miller
(Mayo Clinic), Sonya Anderson (University of Kentucky),
Melissa Swaby (NIA), Eileen Johnson and Pamela Bailie
(University of Rochester), Claudia Kawas, Dana Greenia,
Mukti Patel and Archana Balasubramanian (UC Irvine), and
Robert Padilla, Jamie McCann, Danielle Phelps, and Ishmeal
Conteh (Georgetown University) for organizing and distributing clinical materials and data. We wish to thank Judith
H. Goetzl for expert preparation of graphic illustrations.
Author contributions: analysis of data, writing and/or editing
of manuscript (MSF); evaluation of patients, analysis of
data, writing and/or editing of manuscript (DK); evaluation
of patients, analysis of data, writing and/or editing of manuscript (MM); evaluation of patients, analysis of data, writing
and/or editing of manuscript (AB); laboratory benchwork,
analysis of data (EE); evaluation of patients, analysis of
data, writing and/or editing of manuscript (JBS); evaluation
of patients, analysis of data, writing and/or editing of manuscript (ELA); evaluation of patients, analysis of data, writing
and/or editing of manuscript (RCP); analysis of data, writing
and/or editing of manuscript (HJF); evaluation of patients,
analysis of data, writing and/or editing of manuscript
(BLM); development of analytical methodology, laboratory
benchwork, analysis of data, writing and/or editing of manuscript (EJG).
Funding: Intramural Research Program of the National Institute on Aging (NIA; DK, EE), NIA RO1AG030753 from the
National Institutes of Health (NIH; HJF), UK ADC P30
AG028383(ELA), and an unrestricted grant for technological development from Nanosomix, Inc. (EJG).
Conflicts of interest: Only two authors report possible conflicts of interest. Dr. Boxer declares grants from NIH/NIA,
grants from Tau Research Consortium, grants from Corticobasal Degeneration Solutions, grants, personal fees and nonfinancial support from Archer Biosciences, grants from
Allon Therapeutics, personal fees from Acetylon, personal
fees from Ipierian, grants from Genentech, grants from Bristol Myers Squibb, grants from TauRx, grants from Alzheimer’s Association, grants from Bluefield Project to
Cure FTD, grants from Association for Frontotemporal
Degeneration, grants from Alzheimer’s Drug Discovery
Foundation, grants from EnVivo, grants from C2N Diagnostics, grants from Pfizer, grants from Eli Lilly, outside the
submitted work. Dr. Goetzl has filed a provisional application with the U.S. Patent Office for the platform and methodologies described in this report. These data were presented in
7
part by DK at the 2014 Alzheimer’s Association International Conference in Copenhagen.
RESEARCH IN CONTEXT
1. Case-control study: Abnormal cerebrospinal fluid
(CSF) levels of amyloid b (Ab1–42) and phosphorylation tau (P-tau), and positive central nervous system (CNS) images of amyloid deposits have
diagnostic and predictive value for mild cognitive
impairment and probable Alzheimer’s disease
(AD). However, there is substantial overlap in these
preclinical biomarkers between patients who subsequently develop AD and those who later manifest
other forms of dementia or no signs of dementia,
even when concentrations of these CSF proteins are
considered together or as ratios. This overlap of biomarkers is even greater when plasma levels of these
proteins are used for diagnosis or prediction. We
thus developed a method for quantifying ADrelevant pathogenic proteins in neurally derived
blood exosomes.
2. Interpretation of results: Neurally derived blood exosomal levels of P-T181-tau, P-S396-tau, and Ab1–42
were significantly higher for AD patients than casecontrols, correctly classified 96.4% of AD patients
and were significantly higher for AD patients than for
controls one to ten years before diagnosis of AD.
This high level of prognostic certainty for preclinical
AD combined with the lower morbidity and expense
compared with repeated CSF sampling and neuroimaging procedures emphasizes the potential
importance of this novel blood-based approach to
biomarker testing.
3. Future directions: The clinical usefulness of this
blood exosomal profile of neuropathogenic proteins
will be enhanced by quantification of levels of other
relevant neurally derived exosomal proteins and by
prospective longitudinal studies designed to delineate the neurological course of cognitively normal
subjects with an abnormal blood exosomal profile
of neuropathogenic proteins as contrasted with the
course of those having a normal profile of these proteins.
References
[1] Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a
decade of discoveries paves the way for therapeutic breakthroughs.
Nat Med 2004;10:1055–63.
8
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
[2] Golde TE, Borchelt DR, Giasson BI, Lewis J. Thinking laterally about
neurodegenerative proteinopathies. J Clin Invest 2013;123:1847–55.
[3] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC,
et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367:795–804.
[4] Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue
Dreyfus D, et al. Amyloid imaging and CSF biomarkers in predicting
cognitive impairment up to 7.5 years later. Neurology 2013;
80:1784–91.
[5] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA,
Salvado O, et al. Amyloid beta deposition, neurodegeneration, and
cognitive decline in sporadic Alzheimer’s disease: a prospective
cohort study. Lancet Neurol 2013;12:357–67.
[6] Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al.
Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort
study. Lancet Neurol 2013;12:957–65.
[7] Gama Sosa MA, De Gasperi R, Elder GA. Modeling human neurodegenerative diseases in transgenic systems. Hum Genet 2012;
131:535–63.
[8] Takeda S, Hashimoto T, Roe AD, Hori Y, Spires-Jones TL, Hyman BT.
Brain interstitial oligomeric amyloid beta increases with age and is
resistant to clearance from brain in a mouse model of Alzheimer’s disease. Faseb J 2013;27:3239–48.
[9] Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al.
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;
79:1094–108.
[10] Agarwal R, Tripathi CB. Diagnostic utility of CSF tau and Abeta(42)
in dementia: a meta-analysis. Int J Alzheimers Dis 2011;2011:503293.
[11] Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in
Alzheimer’s disease—current concepts. Mol Neurodegener 2013;
8:20.
[12] Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH,
Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003;60:958–64.
[13] Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H,
Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and
Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;
31:357–67.
[14] Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA,
et al. Plasma amyloid levels and the risk of AD in normal subjects
in the Cardiovascular Health Study. Neurology 2008;70:1664–71.
[15] Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K,
Randall J, et al. Plasma tau levels in Alzheimer’s disease. Alzheimers
Res Ther 2013;5:9.
[16] Fruhbeis C, Frohlich D, Kramer-Albers EM. Emerging roles of exosomes in neuron-glia communication. Front Physiol 2012;3:119.
[17] Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P,
et al. Alzheimer’s disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 2006;103:11172–7.
[18] Vingtdeux V, Sergeant N, Buee L. Potential contribution of exosomes
to the prion-like propagation of lesions in Alzheimer’s disease. Front
Physiol 2012;3:229.
[19] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P,
Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s
disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;
6:734–46.
[20] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM,
et al. Toward defining the preclinical stages of Alzheimer’s disease:
recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:280–92.
[21] Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456–77.
[22] Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M,
Cappa SF, et al. Classification of primary progressive aphasia and its
variants. Neurology 2011;76:1006–14.
[23] Mitsuhashi M, Taub DD, Kapogiannis D, Eitan E, Zukley L,
Mattson MP, et al. Aging enhances release of exosomal cytokine
mRNAs by Abeta1–42-stimulated macrophages. Faseb J 2013;
27:5141–50.
[24] Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively
phosphorylated in cerebrospinal fluid in early Alzheimer disease. J
Biol Chem 2012;287:3842–9.
[25] Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS,
Ivnik RJ, et al. Association of low plasma Abeta42/Abeta40 ratios
with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007;64:354–62.
[26] Seppala TT, Herukka SK, Hanninen T, Tervo S, Hallikainen M,
Soininen H, et al. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based
cohort study. J Neurol Neurosurg Psychiatry 2010;81:1123–7.
[27] Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM,
Younkin SG, et al. Association of plasma beta-amyloid level and
cognitive reserve with subsequent cognitive decline. JAMA 2011;
305:261–6.
[28] Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR,
Macarthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014;20:415–8.
8.e1
M.S. Fiandaca et al. / Alzheimer’s & Dementia - (2014) 1-8
Table S1
Anti-NCAM-1 vs. anti-L1CAM antibodies for enrichment of neurally derived exosomes
AD (n 5 6)
CD81
Total tau
PS-396 tau
PT-181 tau
Ab1–42
NCAM-1
L1CAM
NCAM-1
L1CAM
NCAM-1
L1CAM
NCAM-1
L1CAM
NCAM-1
L1CAM
5.79 6 0.79
5.93 6 0.75
171 6 24.4
167 6 19.4
27.1 6 3.29
26.1 6 3.00
90.5 6 10.1
92.6 6 12.3
14.9 6 3.66
18.0 6 3.14
Controls (n 5 6)
CD81
Total tau
PS-396 tau
PT-181 tau
Ab1–42
NCAM-1
L1CAM
NCAM-1
L1CAM
NCAM-1
L1CAM
NCAM-1
L1CAM
NCAM-1
L1CAM
5.90 6 0.69
5.95 6 0.67
158 6 18.8
154 6 18.6
7.38 6 0.46
7.32 6 0.49
37.4 6 6.73
37.7 6 6.24
4.18 6 1.70
4.07 6 1.45
Abbreviations: NCAM-1, type 1 neural cell adhesion molecule; L1CAM, L1 cell adhesion molecule; AD, Alzheimer’s disease; Ab1–42, amyloid b 1–42.
NOTE. Each value is the mean 6 SEM (pg/ml; ng/ml for CD81) for six determinations of proteins isolated from neurally derived exosomes.
ROC Curves for AC vs. AD
1.0
Sensitivity
0.8
0.6
0.4
Total tau (pg/ml)
p-T181-tau (pg/ml)
p-S396-tau (pg/ml)
Ab(1-42) (pg/ml)
Discriminant scores from
final stepwise model
Reference Line
0.2
0.0
0.0
0.2
0.4
0.6
0.8
1.0
1 - Specificity
Fig. S1. Receiver operating characteristic (ROC) curves for the classification of patients with Alzheimer’s disease (AD) vs. controls (AC) based on
exosomal levels of total tau, P-181-tau, P-S396-tau, amyloid b (Ab1–42),
and using a discriminant model sequentially incorporating exosomal P181-tau, P-S396-tau, and Ab1–42 values.